News & Media
News and features
14 November 2008Interim Results for the six months ended 30 September 2008
Notification of Interim Results
Minster Pharmaceuticals plc (AIM: MPM), announces that its interim results for the half year ended 30 September 2008 will be announced on Friday 14 November 2008.
Read more
Positive results from Phase II trial in Denmark of tonabersat in the prevention of migraine with aura
Tonabersat highlighted at AHS Symposium
Minster is pleased to announce that, Professor David W Dodick, MD Dept of Neurology, Mayo Clinic, Scottsdale, gave a presentation - Gap Junction Blockers: Targeting Migraine Prevention, at a satellite symposium at the AHS’s 50th Meeting
Read more
American Headache Society 50th Scientific Meeting
Minster is pleased to announce that a scientific paper on tonabersat, will be the subject of a presentation today at the 50th Annual Scientific Meeting of the American Headache Society (AHS).
Read more
Grant of Share Options to Directors
Read more
Annual General Meeting
Read more
Result of Annual General Meeting
Read more
Minster Pharmaceuticals plc (AIM: MPM), is pleased to announce that its Phase IIb TEMPUS study is now fully enrolled.
Read more
Annual Report and Financial Statements
Minster Pharmaceuticals Plc announces that it has posted to shareholders the Annual Report and Financial Statements for the year ended 31 March 2008,
Read more
Appointment of US development and marketing consultant
Preliminary Announcement of Audited Results for the year ended 31 March 2008
Annual Report and Financial Statement 2008
Phase II migraine with aura trial fully enrolled
Minster Pharmaceuticals is pleased to announce that its Phase II trial in Denmark of tonabersat in the prevention of migraine with aura is now fully enrolled.
Read more
TEMPUS study enrols first 125 patients
Minster Pharmaceuticals is pleased to announce that 125 patients have now been enrolled in the Company’s TEMPUS study of tonabersat in the preventive treatment of migraine, representing 25 per cent of the patients planned to take part in the trial.
Read more